SkinBioTherapeutics – “Business update”, expect shares to respond positively on further updates soon: BUY!
By Tom Winnifrith and Steve Moore | Sunday 20 February 2022
Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
SkinBioTherapeutics (SBTX) has published a “Business update” announcement including that it has now progressed to the second phase of its AxisBiotix-Ps food supplement for psoriasis product commercialisation strategy and that the SkinBiotix active ingredient project with Sederma is on track. Sounds good!
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism
Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.